跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SHP2 inhibitors (cancer)
首页
药物
SHP2 inhibitors (cancer)
SHP2 inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
(S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO[1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER
EP 4067358 A1
申请人: C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING
优先权: 2021
CN
EP
US
WO
5 件公开
SHP2 inhibitor monotherapy and uses thereof
US 12390469 B2
申请人: HUYABIO INT LLC
优先权: 2022
US
2 件公开
CN 117642167 A
申请人: HUYA BIOSCIENCE INT LLC
优先权: 2022
CN
6-(4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL)-3-(2,3-DICHLOROPHENYL)-2-METHYLPYRIMIDIN-4(3H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS PTPN11 (SHP2) INHIBITORS FOR TREATING CANCER
EP 4356973 A3
申请人: NAVIRE PHARMA INC
优先权: 2018
EP
PD-1 related cancer therapy
US 11110171 B2
申请人: UNIV NEW YORK
优先权: 2018
US
SHP2 inhibitors and uses thereof
US 10561655 B2
申请人: SYNBLIA THERAPEUTICS INC
优先权: 2019
US
CN 114502165 A
申请人: SUZHOU PURHE MEDICAL TECH CO LTD
优先权: 2019
CN
Methods of administering SHP2 inhibitors and treating cancer
CN 114929279 A
申请人: REVOLUTION MEDICINES INC
优先权: 2020
CN
Pharmaceutical combination comprising TNO155 and nazatinib
CN 115397421 A
申请人: NOVARTIS AG
优先权: 2020
CN
Application of FAK inhibitor in preparation of SHP2 inhibitor sensitizing drug
CN 111658777 A
申请人: SECOND MILITARY MEDICAL UNIV
优先权: 2020
CN
Pharmaceutical combinations of SOS1 inhibitors for treatment and/or prevention of cancer
CN 116723843 A
申请人: LUPIN LTD
优先权: 2021
CN
NOVEL THERAPEUTIC MOLECULES TARGETING THE H-RAS ISOFORM WITH G12D MUTATION INVOLVED IN CANCER FORMATION
US 20250049829 A1
申请人: UNIV ISTANBUL MEDIPOL
优先权: 2021
US
第 1 / 2 页
上一页
下一页
药物
反馈